Low-dose naltrexone (LDN) for weight loss: what the trials measured
Reviewed 20 sourcesPublished by PepVault
Does low-dose naltrexone cause weight loss? The human naltrexone weight trials in one table, with Contrave's label numbers and Wegovy and Zepbound beside them.

- Last reviewed
- Sources
- 20
- Questions
- 8
- Compounds
- 3
The short answer
No randomized trial has tested low-dose naltrexone (LDN, about 1 to 4.5 mg a day) for weight loss. The weight data come from higher doses: naltrexone alone at 25 to 300 mg did not beat placebo in obesity trials, and Contrave, 32 mg of naltrexone with bupropion, took off 5.4% against 1.3% on placebo in a year. Wegovy's main trial reached 14.9%, Zepbound's 20.9%.
Evidence: No randomized trial of low-dose naltrexone (1 to 4.5 mg) for weight; small controlled trials of naltrexone alone at 25 to 300 mg; phase 3 trials for Contrave, Wegovy and Zepbound.

Does low-dose naltrexone cause weight loss?
Nobody has measured it in a trial. LDN is naltrexone, an opioid-blocking drug approved at 50 mg for alcohol and opioid dependence, taken at a tenth of that or less and prescribed off-label (pepvault.app/glossary/off-label), for a use the label does not cover1. Its trials, in fibromyalgia, Crohn's disease, MS and long COVID, measured pain, fatigue and disease activity, not weight; our LDN guide (pepvault.app/guides/low-dose-naltrexone) sets those out.
The approved label mentions weight only in passing: increased appetite, weight loss and weight gain all appear among the events seen in fewer than 1% of people in its opioid-addiction trials1. So the honest answer to "does LDN make you lose weight" is that every number below comes from a different dose. Here is which naltrexone is which:
| Form | Naltrexone a day | What it is |
|---|---|---|
| Low-dose naltrexone (LDN) | About 1 to 4.5 mg | Off-label, usually made by a compounding pharmacy; no weight trial |
| Older "low-dose" trials | 25 mg | Half the approved tablet; tested in smokers and in people on antipsychotics811 |
| Contrave (with bupropion 360 mg) | 32 mg | FDA-approved to reduce excess weight and keep it off, in adults with obesity or overweight and a related condition2 |
| Naltrexone tablets | 50 mg | FDA-approved for alcohol and opioid dependence1 |
| 1980s obesity trials | 50 to 300 mg | Tested for weight loss; did not beat placebo567 |
Watch the word "low" when you read about it. In the smoking papers, "low-dose naltrexone" means 25 mg, more than five times the LDN dose13.

What did trials of naltrexone on its own find for weight?
The idea is old: the body's own opioids help regulate eating, and in animals blocking them cuts food intake5. In people, it mostly did not turn into weight loss. These are the trials; all but the 4-day feeding study were blinded and against placebo (pepvault.app/glossary/placebo):
| Trial | People, dose, length | Weight result |
|---|---|---|
| Atkinson 19855 | 60 adults with obesity, 50 or 100 mg, 8 weeks | No significant loss against placebo; women alone lost 1.7 kg |
| Malcolm 19856 | 41 adults with obesity, 200 mg, 10 weeks | 1.8 kg on naltrexone vs 1.5 kg on placebo: no difference |
| Mitchell 19877 | Men with obesity on a diet, 300 mg, 8 weeks | No advantage over placebo |
| Spiegel 198719 | 17 men with obesity, 25 rising to 200 mg, 4 days | Lunch intake fell 30%; body weight did not change |
| Tek 2014 pilot8 | 24 women with schizophrenia, 25 mg, 8 weeks | Lost 3.4 kg vs gained 1.4 kg on placebo |
| Yale, NCT018660989 | 144 adults on antipsychotics, 25 or 50 mg, 52 weeks | +0.7 kg (25 mg) and −1.0 kg (50 mg) vs −0.2 kg on placebo: no difference |
The longest and largest of them, the Yale year-long trial, found nothing on the scale9, and a 2025 systematic review of the antipsychotic trials found that naltrexone did not separate from placebo on weight or BMI (pepvault.app/glossary/bmi)10. The 8-week pilot that looked promising did not hold up at 52 weeks89.
One small open study is often quoted: 10 women with PCOS took 50 mg for 6 months and their BMI fell from 29.9 to 26.118. With no placebo group, it cannot say how much of that was the drug. The high-dose trials also saw liver enzymes rise in a few people, at 50 to 300 mg567.
Does naltrexone stop weight gain when you quit smoking?
A little, and this is where the low-milligram data are strongest. In a 400-person Yale trial, smokers who quit on 25 mg plus a nicotine patch gained 0.7 kg in 6 weeks, against 1.9 kg on placebo11. Pooling the two largest trials (25 to 100 mg), women on naltrexone gained 3.3 kg by 6 months against 5.5 kg on placebo; men saw no difference12. In a 27-week trial in smokers worried about weight, the gap (6.8 lb vs 9.7 lb) was not significant13.
So naltrexone at 25 to 100 mg slowed weight gain after quitting, by a kilogram or two. None of these trials tested 4.5 mg, and none tested weight loss in people trying to lose weight.
Why does naltrexone work with bupropion?
The pair was designed to work on two parts of the brain at once. Bupropion, an antidepressant, activates POMC neurons, the cells in the hypothalamus that signal fullness; naltrexone blocks the opioid signals that push back against that fullness and against weight loss14. The Contrave label adds what the lab work showed: together they raised POMC firing in cells and cut food intake when given into the brain's reward area in mice2.
The dose-finding trial bore it out in people. In 419 adults over 24 weeks, each naltrexone-plus-bupropion arm, at 16, 32 or 48 mg of naltrexone, beat placebo by 3.5 to 4.7 percentage points of body weight and beat naltrexone alone14. The phase 3 trials, COR-I among them, then used 32 mg, the dose on the label2.
How much weight does Contrave take off?
About 4% to 8% of body weight in a year, in the three 56-week trials the label tables, against 1.3% to 4.9% on placebo2. The label's numbers, with diet and exercise counselling in every arm:
| Contrave trial (56 weeks) | Weight change, Contrave vs placebo | Lost 5% or more | Lost 10% or more |
|---|---|---|---|
| COR-I | −5.4% vs −1.3% | 42% vs 17% | 21% vs 7% |
| COR-BMOD (intensive behaviour program) | −8.1% vs −4.9% | 57% vs 43% | 35% vs 21% |
| COR-Diabetes (type 2 diabetes) | −3.7% vs −1.7% | 36% vs 18% | 15% vs 5% |
The label builds in a check: if someone has not lost at least 5% after 12 weeks on the full dose, it says to stop, because meaningful loss is unlikely to follow2. Nausea was the most common side effect, 32.5% against 6.7% on placebo, followed by constipation and headache2. Because bupropion is also an antidepressant, the label carries a boxed warning (pepvault.app/glossary/boxed-warning) about suicidal thoughts in young people2.
How does that compare with Wegovy and Zepbound?
Wegovy's trial took off about three times Contrave's, Zepbound's about four times, counted raw or minus placebo (Contrave 4.1 points over placebo, Wegovy 12.4, Zepbound 17.8). These are each drug's main obesity trial as its own label reports it: different trials, lengths, people and years, not a head-to-head test.
| Drug, trial | Length | Weight change, drug vs placebo | Lost 5% or more | Lost 10% or more |
|---|---|---|---|---|
| LDN, 1 to 4.5 mg | No trial | Not measured | Not measured | Not measured |
| Contrave, COR-I2 | 56 weeks | −5.4% vs −1.3% | 42% vs 17% | 21% vs 7% |
| Wegovy 2.4 mg, STEP 1315 | 68 weeks | −14.9% vs −2.4% | 83.5% vs 31.1% | 66.1% vs 12.0% |
| Zepbound 15 mg, SURMOUNT-1416 | 72 weeks | −20.9% vs −3.1% | 90.9% vs 34.5% | 83.5% vs 18.8% |
Whatever you take, the scale is the measure the trials used. PepVault's weight log draws your trend week by week, so you can see your own line against these numbers and bring it to your prescriber. Track your weight in PepVault
Wegovy is semaglutide (pepvault.app/peptides/semaglutide) and Zepbound is tirzepatide (pepvault.app/peptides/tirzepatide); the two labels sit side by side at pepvault.app/drugs/compare/wegovy-vs-zepbound.
Is anyone testing LDN for weight now?
One registered trial includes it. AgelessRx, a telehealth longevity company, is randomizing 150 of its own patients who lost at least 15 lb on a GLP-1 to four ways of stopping it: metformin, metformin with rapamycin, metformin with LDN, or vitamin C as the control, with weight reported by the patients every 4 weeks20.
Two details matter. Its LDN arm climbs from 1.5 mg twice a day to 4.5 mg twice a day, 9 mg a day, twice the usual LDN dose. And it is open-label (pepvault.app/glossary/open-label): everyone knows what they take. The record still reads "recruiting", with its main results due in August 2025 and no update since July 2025; no results are posted20.
That makes it the only registered trial we found with an LDN arm and a weight outcome, and it asks a narrower question: whether LDN with metformin slows the regain after stopping a GLP-1, not whether LDN takes weight off. Our guide on keeping weight off after a GLP-1 (pepvault.app/guides/keeping-weight-off-after-a-glp-1) has what the stopping trials found.
Can you take LDN with a GLP-1 or Contrave?
Neither the Wegovy nor the Zepbound label names naltrexone; both note that they slow stomach emptying, which can change how other tablets are absorbed34. The AgelessRx trial gives LDN beside a tapering semaglutide dose20. Contrave is different: its label says taking it with other naltrexone products is not recommended, so LDN on top of Contrave doubles up the same drug2.
The rule that matters most is the opioid one. Naltrexone in any dose blocks opioid painkillers and can bring on withdrawal in someone taking methadone or buprenorphine; the labels of both naltrexone and Contrave rule those combinations out12. In 2026, doctors in Arizona reported a man on methadone who went into severe withdrawal after his first dose of a naltrexone weight-loss kit bought through an online telehealth service17.
PepVault logs a daily tablet with a reminder at the time you set, so each dose sits in one history beside your weight. Set reminders in PepVault
Commonly reported: some people on LDN describe fewer cravings and less evening snacking, others notice no change on the scale, and vivid dreams in the first weeks are the side effect mentioned most.
When to get help Anyone taking naltrexone at any dose who needs pain relief for surgery, dental work or an injury should tell the treating clinician first, because opioid painkillers will not work as expected1.
Sources
- Naltrexone hydrochloride tablets USP 50 mg, prescribing information (RemedyRepack). DailyMed, SPL version 10, effective November 11, 2026 (published November 16): Indications and usage; Contraindications; Adverse reactions. dailymed.nlm.nih.gov
- Contrave (naltrexone HCl and bupropion HCl) extended-release tablets, prescribing information. Nalpropion Pharmaceuticals. DailyMed, SPL version 27, Nov 2025: sections 1, 2, 4, 6.1, 12.1, 12.2, 14. dailymed.nlm.nih.gov
- Wegovy (semaglutide) injection, prescribing information, section 14.2, Table 8 (Study 2, STEP 1). Novo Nordisk. DailyMed, SPL version 19, Jun 2026. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) injection, prescribing information, section 14 (Study 1, SURMOUNT-1). Eli Lilly. DailyMed, SPL version 40, Sep 2026. dailymed.nlm.nih.gov
- Atkinson RL et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 1985. PubMed 4042525
- Malcolm R et al. A controlled trial of naltrexone in obese humans. Int J Obes. 1985. PubMed 3908352
- Mitchell JE et al. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry. 1987. PubMed 3790639
- Tek C et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. J Clin Psychopharmacol. 2014. PubMed 25102328
- ClinicalTrials.gov NCT01866098. Naltrexone for antipsychotic-induced weight gain (Yale University), posted results, accessed November 20, 2026. clinicaltrials.gov
- Lee K et al. Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: a systematic review and meta-analysis of clinical trial data. J Psychopharmacol. 2025. PubMed 40406979
- O'Malley SS et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006. PubMed 16567607
- King AC et al. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013. PubMed 23177384
- Toll BA et al. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend. 2010. PubMed 20542391
- Greenway FL et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009. PubMed 19846734
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- Summers PJ et al. Probable naltrexone-precipitated opioid withdrawal in a patient receiving methadone maintenance after use of a weight-loss medication obtained through a direct-to-consumer telemedicine platform: a case report. Subst Abuse Treat Prev Policy. 2026. PubMed 42989360
- Fruzzetti F et al. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril. 2002. PubMed 12009347
- Spiegel TA et al. Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav. 1987. PubMed 3628520
- ClinicalTrials.gov NCT07092618. Effectiveness of alternative therapies in maintaining weight loss achieved by GLP-1 medications post-cessation (AgelessRx), accessed November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.